RESEARCH MONOGRAPH · KDC-MN-250

Gepirone

May 9, 2026 Kodiac biolabs Research Revised May 11, 2026 2 min read

Our opinion on this compound

68/100

The 5-HT1A partial agonist that took 30 years to get approved and still feels underused

Look, gepirone is the buspirone cousin that nobody talks about. Same azapirone scaffold, same 5-HT1A partial agonist mechanism, but with a cleaner postsynaptic profile and an FDA approval that took something like three decades of back-and-forth before Exxua finally landed in 2023. The story alone is worth knowing.

What we like about gepirone is the mechanism is unusually well-mapped for a serotonergic. Partial agonism at postsynaptic 5-HT1A in cortex and hippocampus, with autoreceptor desensitization that mirrors what you see when SSRIs eventually start working but without the synaptic 5-HT flood. The trials Fabre and others ran in the 90s and 2000s on the extended-release form showed effect sizes in MDD that werent huge but were real, and notably without the sexual side effect signature that drags down SSRI compliance.

The catch is reliability. Gepirone is one of those compounds where the trial data oscillates more than you'd want. Some studies hit, some miss, and the meta-analyses are middling. Part of that is dose finding, part of it is the partial-agonist profile being inherently more subtle than full agonism. It's not a hit-you-in-the-face compound.

From a research-tool perspective it's interesting precisely because of that subtlety. If you're modeling 5-HT1A pharmacology, gepirone gives you something more selective than buspirone (which has that 1-PP metabolite muddying the picture) and more clinically validated than the experimental ligands like F-15599. We've seen labs use it as a reference compound for postsynaptic 5-HT1A function in cognitive paradigms, which is a reasonable use.

Sourcing is fine. It's a synthetic small molecule with a known synthesis route and decent vendor availability now that it's an approved drug. Purity verification by standard HPLC is straightforward.

Honestly the most interesting thing about gepirone is what its long approval saga says about how risk-averse FDA reviewers became with serotonergics post-fenfluramine. The data was basically there in 2002. We just took 21 more years to get comfortable with it. As a research compound it's a useful tool for 5-HT1A work, and we think it deserves more attention from the academic side than it gets.

Evidence: 70
Mechanism: 80
Reliability: 55
Safety: 80
Sourcing: 78
Value: 65
Signal: 55
Staying power: 62

Plain-language summary Intrigue 64 / 100

Gepirone (Exxua) finally reached FDA approval in 2023, more than thirty years after its initial development at Bristol-Myers Squibb began in the 1980s. The 5-HT1A partial agonist had been rejected by the FDA multiple times before Fabre-Kramer eventually pushed an extended-release formulation across the finish line for major depressive disorder. The selling point versus standard SSRIs is essentially zero sexual dysfunction, which is the side effect that drives many patients off serotonergic antidepressants. Mechanistically it is in the same azapirone family as buspirone but with substantially more 5-HT1A intrinsic activity, which appears to translate into antidepressant rather than just anxiolytic effects. Real-world prescribing data are still accumulating. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

5-HT1A partial agonist

An azapirone 5-HT1A partial agonist developed for major depressive disorder; FDA-approved in 2023 after a 30-year development cycle.

Abstract

Gepirone (4,4-dimethyl-1-{4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl}-2,6-piperidinedione; CAS 83928-76-1; molecular formula C19H29N5O2; molecular weight 359.47) is an azapirone 5-HT1A partial agonist developed by Bristol-Myers Squibb and Fabre-Kramer over a 30-plus-year development cycle, ultimately approved by the FDA in 2023 under the trade name Exxua for major depressive disorder. The compound is structurally and mechanistically similar to buspirone: 5-HT1A affinity approximately 19 nM with intrinsic activity approximately 60 percent; minimal D2 affinity; active metabolite 1-PP. Distinct from buspirone in development trajectory (positioned for depression rather than anxiety) and in being formulated as extended-release for once-daily dosing. The approved indication is MDD; the principal selling point versus SSRIs is absence of sexual dysfunction (a major SSRI tolerability complaint). Plasma half-life is 18 hours (ER formulation); metabolism is via CYP3A4. Used as a reference 5-HT1A partial agonist with depression-focused clinical development.

Mechanism of action

5-HT1A partial agonist (intrinsic activity ~60 percent). Same azapirone class as buspirone. Approved for MDD; absent sexual dysfunction.

Reported research dose ranges

Clinical 18.2 to 72.6 mg per oral administration daily (ER). Rodent studies 1 to 30 mg/kg/day.

References

Cooper TB, et al. Gepirone: pharmacology and clinical development. Neuropsychopharmacology 1992.
Feiger AD, et al. Gepirone extended-release in the treatment of major depressive disorder. J Clin Psychopharmacol 2003.
FDA Approval Package for Exxua (gepirone) extended-release tablets. 2023.

Read the full monograph

The full reference document is available below as a PDF embed and download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-250 Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Gepirone

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs